Autistic Disorder

Bulimia

Obesity

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">FINTEPLA oral solution contains 2.2 mg/mL fenfluramine, equivalent to 2.5 mg/mL of the hydrochloride salt.</p><p>The active ingredient, fenfluramine hydrochloride, is designated chemically as N-ethyl-α- methyl-3-(trifluoromethyl)phenethylamine hydrochloride.</p><p>The structural formula is:</p><p><img alt="Chemical Structure" src="fintepla-01.jpg"/></p><p>Fenfluramine hydrochloride is a white to off-white crystalline solid. The pKa of fenfluramine is 10.2.</p><p>FINTEPLA is a clear, colorless solution, pH 5.</p><p>FINTEPLA contains the following inactive ingredients: cherry flavor, citric acid, ethylparaben hydroxyethylcellulose, methylparaben, potassium citrate, sucralose, and water.</p><p>FINTEPLA contains no ingredient made from gluten-containing grain (wheat, barley, or rye), and contains not more than 0.1% of carbohydrates, which is solely derived from the cherry flavor.</p></section>

Fintepla

fenfluramine 2.2 MG/ML Oral Solution

fenfluramine 2.2 MG/ML Oral Solution [Fintepla]

fenfluramine

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Fintepla Presciption Authorization & Patient Referral Form 

Fintepla Presciption Authorization & Patient Referral Form - Spanish

Echo Locator 

Zogenix Provider Portal

Enroll in Patient Savings Program 

Prescribing Fintepla

Other HCP Resources 

About Fintepla: Dravet Syndrome

About Fintepla: Lennox-Gastuat Syndrome

Side Effects & REMS Program 

Fintepla Start Guide 

Patient Resources 

Onward Support Program

Patient Stories 

FAQS: Dravet Syndrome & Lennox-Gastaut Syndrome 

Echocardiogram Brochure

Patient Brochure: Dravet Syndrome

Doctor Discussion Guide: Dravet Syndrome

Patient Brochure: Lennox-Gastaut Syndrome

Doctor Discussion Guide: Lennox-Gastaut Syndrome

Instructions For Use: Dravet Syndrome 

Instructions For Use: Lennox-Gastaut Syndrome (LGS)